糸球体腎炎の世界市場レポート 2025年

糸球体腎炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.0％で141億4,000万米ドルに成長します。予測期間の成長は、糖尿病罹患率の増加、高齢化、ヘルスケア支出の増加、透析患者数の増加、自己免疫疾患患者の急増などに起因すると考えられます。この期間に予想される主要動向としては、新しい治療法の導入、診断技術の発展、新規治療の開発、企業間の協力関係の強化、免疫グロブリン静注療法の普及などが挙げられます。

腎障害の有病率の増加が糸球体腎炎市場の成長を牽引すると予想されます。腎障害には、老廃物の濾過、体液バランスの維持、不可欠な身体機能の調節といった腎臓の機能を損なうさまざまな疾患が含まれます。これらの疾患の罹患率の増加は、人口の高齢化、糖尿病や高血圧などの慢性疾患の罹患率の増加、生活習慣などの要因に関連しています。腎臓疾患は、免疫系の機能不全、慢性炎症、構造的損傷を引き起こし、最終的に腎臓の機能低下につながることで、糸球体腎炎に寄与します。例えば、2024年12月、オーストラリア保健福祉ラボは、慢性腎臓病（CKD）の死亡率が2021年に4.2％、2022年に6.2％増加したと報告しました。さらに、CKDは2021年から22年にかけて約200万件の入院に記録され、オーストラリアの全入院の18％を占めました。腎臓疾患がより一般的になるにつれて、糸球体腎炎治療に対する需要は高まると予想されます。

糸球体腎炎市場の主要企業は、アンメット・メディカル・ニーズを満たし、患者の転帰を改善するために、革新的な非免疫抑制性治療の開発に注力しています。非免疫抑制治療は、免疫機能を低下させることなく病態を治療することを目的としています。2024年9月、米国のバイオ医薬品会社であるトラベール・セラピューティクス社は、一般的な腎臓病であるIgA腎症の治療としてFDAの承認を取得したFILSPARI（sparsentan）を発売しました。FILSPARIは、罹患患者の腎機能低下を有意に遅らせることが証明された唯一の非免疫抑制治療です。今回の承認は、IgA腎症の治療における大きな進歩であり、これまで選択肢が限られていた患者に新たな選択肢を提供するものです。Travereの成功は、腎臓病に対する革新的な治療法の開発に対するコミットメントの高まりを反映しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の糸球体腎炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の糸球体腎炎市場：成長率分析
• 世界の糸球体腎炎市場の実績：規模と成長、2019～2024年
• 世界の糸球体腎炎市場の予測：規模と成長、2024～2029年、2034年
• 世界の糸球体腎炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糸球体腎炎市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性糸球体腎炎
• 慢性糸球体腎炎
• 世界の糸球体腎炎市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 尿検査と血液検査
• 画像検査
• 腎生検
• その他
• 世界の糸球体腎炎市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬
• 手術
• 透析
• その他
• 世界の糸球体腎炎市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• その他
• 世界の糸球体腎炎市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• その他
• 世界の糸球体腎炎市場、急性糸球体腎炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 感染後糸球体腎炎
• IgA腎症
• ループス腎炎
• 急速進行性糸球体腎炎（RPGN）
• グッドパスチャー症候群
• 世界の糸球体腎炎市場、慢性糸球体腎炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 巣状分節性糸球体硬化症（FSGS）
• 膜性腎症
• 微小変化病
• アルポート症候群
• 糖尿病性腎症
• 高血圧性腎硬化症

第7章 地域別・国別分析

• 世界の糸球体腎炎市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の糸球体腎炎市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糸球体腎炎市場：競合情勢
• 糸球体腎炎市場：企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Novartis International AG
  • Eli Lilly and Company

第31章 その他の大手企業と革新的企業

• Asahi Kasei Medical Co. Ltd.
• Boehringer Ingelheim International GmbH
• DaVita Inc.
• Biogen Inc.
• Merit Medical Systems Inc.
• Apellis Pharmaceuticals Inc.
• MorphoSys AG
• Travere Therapeutics Inc.
• Vera Therapeutics Inc.
• Calliditas Therapeutics AB
• Omeros Corporation
• Otsuka Pharmaceutical Co. Ltd.
• Aurinia Pharmaceuticals Inc.
• Alexion Pharmaceuticals Inc.
• NovelMed Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 糸球体腎炎市場、2029年：新たな機会を提供する国
• 糸球体腎炎市場、2029年：新たな機会を提供するセグメント
• 糸球体腎炎市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys responsible for removing waste and excess fluids from the blood. It can be caused by infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in the urine, proteinuria, and swelling. If left untreated, it can progress to chronic kidney disease or kidney failure.

The primary types of glomerulonephritis include acute and chronic glomerulonephritis. Acute glomerulonephritis is a sudden inflammation of the kidneys, often triggered by infections, and requires prompt treatment to prevent long-term complications. Diagnosis is conducted through various methods, including urine and blood tests, imaging tests, and kidney biopsy. Treatment options include medication, surgery, dialysis, and other interventions. The condition is managed through multiple distribution channels, including hospital pharmacies and retail pharmacies, and is utilized by various end-users such as hospitals and specialty clinics.

The glomerulonephritis market research report is one of a series of new reports from The Business Research Company that provides glomerulonephritis market statistics, including the glomerulonephritis industry global market size, regional shares, competitors with the glomerulonephritis market share, detailed glomerulonephritis market segments, market trends, and opportunities, and any further data you may need to thrive in the glomerulonephritis industry. This glomerulonephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glomerulonephritis market size has grown strongly in recent years. It will grow from $11.06 billion in 2024 to $11.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period was driven by the rising prevalence of kidney disorders, the occurrence of infections such as post-streptococcal glomerulonephritis, increased research and development efforts, a higher incidence of kidney failure, and greater awareness of kidney diseases.

The glomerulonephritis market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The projected growth in the forecast period can be attributed to the increasing incidence of diabetes, an aging population, rising healthcare expenditures, a growing number of dialysis patients, and a surge in autoimmune disease cases. Key trends expected during this period include the introduction of new treatments and therapies, advancements in diagnostic technologies, the development of novel therapeutics, increased collaboration between companies, and the growing use of intravenous immunoglobulin therapy.

The increasing prevalence of kidney disorders is expected to drive the growth of the glomerulonephritis market. Kidney disorders encompass a range of conditions that impair the kidneys' ability to filter waste, maintain fluid balance, and regulate essential bodily functions. The rising incidence of these disorders is linked to factors such as aging populations, increasing rates of chronic diseases such as diabetes and hypertension, and lifestyle habits. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, ultimately leading to impaired kidney function. For example, in December 2024, the Australian Institute of Health and Welfare reported that chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. Additionally, CKD was recorded in approximately 2 million hospitalizations in 2021-22, accounting for 18% of all hospitalizations in Australia. As kidney disorders become more prevalent, the demand for glomerulonephritis treatments is expected to rise.

Leading companies in the glomerulonephritis market are focusing on developing innovative non-immunosuppressive treatments to meet unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are designed to treat conditions without compromising immune function. In September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, launched FILSPARI (sparsentan), which received FDA approval for treating IgA nephropathy, a common kidney disease. FILSPARI is the only non-immunosuppressive treatment proven to significantly slow the decline of kidney function in affected patients. This approval marks a significant advancement in the treatment of IgA nephropathy, providing a new option for patients who previously had limited choices. Travere's success reflects a growing commitment to developing innovative therapies for kidney disease.

In May 2023, Rona Therapeutics Inc., a China-based biopharmaceutical company, entered into a partnership with Keymed Biosciences Inc. to develop novel treatments for glomerulonephritis. This collaboration focuses on creating first-in-class siRNA therapeutics to address the urgent need for new medicines in this field. Keymed Biosciences Inc., also based in China, specializes in biotechnology and is dedicated to advancing treatments for glomerulonephritis.

Major players in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and NovelMed Therapeutics Inc.

North America was the largest region in the glomerulonephritis market in 2024. The regions covered in glomerulonephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Glomerulonephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glomerulonephritis market consists of revenues earned by entities by providing services such as immunosuppressive therapy, blood pressure control, and kidney transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The glomerulonephritis market also includes sales of complement-level test kits, urine protein test kits, and medication. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glomerulonephritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glomerulonephritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glomerulonephritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glomerulonephritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis
• 2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis
• 3) By Treatment: Medication; Surgery; Dialysis; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome
• 2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Minimal Change Disease; Alport Syndrome; Diabetic Nephropathy; Hypertensive Nephrosclerosis
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca PLC; Novartis International AG; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glomerulonephritis Market Characteristics

3. Glomerulonephritis Market Trends And Strategies

4. Glomerulonephritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Glomerulonephritis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glomerulonephritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glomerulonephritis Market Growth Rate Analysis
• 5.4. Global Glomerulonephritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glomerulonephritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glomerulonephritis Total Addressable Market (TAM)

6. Glomerulonephritis Market Segmentation

• 6.1. Global Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Glomerulonephritis
• Chronic Glomerulonephritis
• 6.2. Global Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urine And Blood Test
• Imaging Tests
• Kidney Biopsy
• Other Diagnosis
• 6.3. Global Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Surgery
• Dialysis
• Other Treatments
• 6.4. Global Glomerulonephritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.5. Global Glomerulonephritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.6. Global Glomerulonephritis Market, Sub-Segmentation Of Acute Glomerulonephritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post-infectious Glomerulonephritis
• IgA Nephropathy
• Lupus Nephritis
• Rapidly Progressive Glomerulonephritis (RPGN)
• Goodpasture Syndrome
• 6.7. Global Glomerulonephritis Market, Sub-Segmentation Of Chronic Glomerulonephritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Segmental Glomerulosclerosis (FSGS)
• Membranous Nephropathy
• Minimal Change Disease
• Alport Syndrome
• Diabetic Nephropathy
• Hypertensive Nephrosclerosis

7. Glomerulonephritis Market Regional And Country Analysis

• 7.1. Global Glomerulonephritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glomerulonephritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glomerulonephritis Market

• 8.1. Asia-Pacific Glomerulonephritis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glomerulonephritis Market

• 9.1. China Glomerulonephritis Market Overview
• 9.2. China Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glomerulonephritis Market

• 10.1. India Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glomerulonephritis Market

• 11.1. Japan Glomerulonephritis Market Overview
• 11.2. Japan Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glomerulonephritis Market

• 12.1. Australia Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glomerulonephritis Market

• 13.1. Indonesia Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glomerulonephritis Market

• 14.1. South Korea Glomerulonephritis Market Overview
• 14.2. South Korea Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glomerulonephritis Market

• 15.1. Western Europe Glomerulonephritis Market Overview
• 15.2. Western Europe Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glomerulonephritis Market

• 16.1. UK Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glomerulonephritis Market

• 17.1. Germany Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glomerulonephritis Market

• 18.1. France Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glomerulonephritis Market

• 19.1. Italy Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glomerulonephritis Market

• 20.1. Spain Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glomerulonephritis Market

• 21.1. Eastern Europe Glomerulonephritis Market Overview
• 21.2. Eastern Europe Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glomerulonephritis Market

• 22.1. Russia Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glomerulonephritis Market

• 23.1. North America Glomerulonephritis Market Overview
• 23.2. North America Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glomerulonephritis Market

• 24.1. USA Glomerulonephritis Market Overview
• 24.2. USA Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glomerulonephritis Market

• 25.1. Canada Glomerulonephritis Market Overview
• 25.2. Canada Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glomerulonephritis Market

• 26.1. South America Glomerulonephritis Market Overview
• 26.2. South America Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glomerulonephritis Market

• 27.1. Brazil Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glomerulonephritis Market

• 28.1. Middle East Glomerulonephritis Market Overview
• 28.2. Middle East Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glomerulonephritis Market

• 29.1. Africa Glomerulonephritis Market Overview
• 29.2. Africa Glomerulonephritis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glomerulonephritis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glomerulonephritis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glomerulonephritis Market Competitive Landscape And Company Profiles

• 30.1. Glomerulonephritis Market Competitive Landscape
• 30.2. Glomerulonephritis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Glomerulonephritis Market Other Major And Innovative Companies

• 31.1. Asahi Kasei Medical Co. Ltd.
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. DaVita Inc.
• 31.4. Biogen Inc.
• 31.5. Merit Medical Systems Inc.
• 31.6. Apellis Pharmaceuticals Inc.
• 31.7. MorphoSys AG
• 31.8. Travere Therapeutics Inc.
• 31.9. Vera Therapeutics Inc.
• 31.10. Calliditas Therapeutics AB
• 31.11. Omeros Corporation
• 31.12. Otsuka Pharmaceutical Co. Ltd.
• 31.13. Aurinia Pharmaceuticals Inc.
• 31.14. Alexion Pharmaceuticals Inc.
• 31.15. NovelMed Therapeutics Inc.

32. Global Glomerulonephritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glomerulonephritis Market

34. Recent Developments In The Glomerulonephritis Market

35. Glomerulonephritis Market High Potential Countries, Segments and Strategies

• 35.1 Glomerulonephritis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glomerulonephritis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glomerulonephritis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer